Study guide

11.2 Medical & Obstetric Complications of Pregnancy

USMLE Step 2 CK Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Human Development & Well-Patient Care

1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening

2 Chapter 2: Immune System & Immunologic Disorders

2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles

3 Chapter 3: Blood & Lymphoreticular System

3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders

4 Chapter 4: Behavioral Health & Psychiatric Disorders

4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology

5 Chapter 5: Nervous System & Special Senses

5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies

6 Chapter 6: Musculoskeletal System & Dermatology

6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders

7 Chapter 7: Cardiovascular System

7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease

8 Chapter 8: Respiratory System

8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases

9 Chapter 9: Gastrointestinal System

9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis

10 Chapter 10: Renal, Urinary & Reproductive Systems

10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease

11 Chapter 11: Pregnancy, Childbirth & Puerperium

11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management

12 Chapter 12: Endocrine System

12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology

13 Chapter 13: Multisystem Processes & Critical Care

13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens

14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation

14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine

15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice

15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions

11.2 Medical & Obstetric Complications of Pregnancy

Key Takeaways Explain This Topic AI

Preeclampsia is diagnosed after 20 weeks gestation by BP ≥140/90 mmHg on two occasions at least 4 hours apart plus proteinuria (≥300 mg/24h or urine protein:creatinine ratio ≥0.3) or severe features (BP ≥160/110 mmHg, platelets <100,000/mcL, SCr >1.1 mg/dL, transaminases 2x normal, pulmonary edema, or cerebral/visual symptoms).

Intrapartum magnesium sulfate infusion (4-6 g IV loading dose followed by 1-2 g/h) is mandatory for seizure prophylaxis in preeclampsia with severe features and eclampsia; toxicity (loss of DTRs at 8-12 mEq/L, respiratory depression at 12-15 mEq/L) is reversed with 1 g intravenous calcium gluconate.

Gestational Diabetes Mellitus (GDM) screening at 24-28 weeks uses a 1-hour 50g glucose challenge test (threshold ≥130-140 mg/dL), followed by a diagnostic 3-hour 100g oral glucose tolerance test (GDM diagnosed if ≥2 values met: Fasting ≥95, 1-hr ≥180, 2-hr ≥155, 3-hr ≥140 mg/dL). First-line treatment is dietary modification and exercise; insulin is the preferred pharmacotherapy when glycemic targets (fasting <95 mg/dL, 2-hr postprandial <120 mg/dL) fail.

Medical management of unruptured ectopic pregnancy with methotrexate is indicated when the patient is hemodynamically stable, ectopic mass is <3.5 cm without fetal cardiac activity, baseline beta-hCG is <5,000 mIU/mL, and renal/hepatic function is normal.

Placenta previa presents as painless third-trimester vaginal bleeding and requires C-section delivery at 36 0/7 to 37 6/7 weeks; digital vaginal examination is strictly contraindicated prior to transvaginal ultrasound confirmation due to the risk of life-threatening hemorrhage.

Last updated: July 2026

  • Medical & Obstetric Complications of Pregnancy
  • Hypertensive Disorders of Pregnancy

Hypertensive disorders affect 5–10% of pregnancies and represent a leading cause of maternal and perinatal morbidity. Classification is based on gestational age at onset, presence of proteinuria, and organ-specific severe features:

Chronic Hypertension: Blood pressure ≥140/90 mmHg documented prior to pregnancy or before 20 weeks gestation , persisting >12 weeks postpartum.

Gestational Hypertension: New-onset BP ≥140/90 mmHg occurring after 20 weeks gestation in the absence of proteinuria or severe features. Resolves <12 weeks postpartum.

Preeclampsia: New-onset hypertension ( ≥140/90 mmHg on 2 readings at least 4 hours apart) after 20 weeks gestation accompanied by proteinuria ( ≥300 mg/24-hour urine collection , urine protein:creatinine ratio ≥0.3 , or dipstick 2+).

Preeclampsia with Severe Features: Diagnosed when preeclampsia is accompanied by ANY of the following severe criteria (proteinuria is NOT required if severe features are present):

Severe blood pressure elevation: systolic ≥160 mmHg or diastolic ≥110 mmHg on two occasions at least 15 minutes apart

Thrombocytopenia: platelets <100,000/mcL

Impaired liver function: transaminases (AST/ALT) ≥2 times upper limit of normal or severe persistent right upper quadrant / epigastric pain

  • Progressive renal insufficiency: serum creatinine >1.1 mg/dL or doubling of baseline serum creatinine
  • Pulmonary edema
  • New-onset cerebral or visual disturbances (persistent severe frontal headache, scotomas, blurred vision)

Eclampsia: Development of new-onset tonic-clonic seizures in a patient with preeclampsia. Managed with IV magnesium sulfate, blood pressure stabilization, and emergency delivery.

HELLP Syndrome: A severe variant of preeclampsia defined by Hemolysis (microangiopathic hemolytic anemia with schistocytes, serum total bilirubin >1.2 mg/dL , and LDH >600 U/L ), Elevated Liver enzymes (AST/ALT ≥2x upper limit of normal), and Low Platelets ( <100,000/mcL ). Carries high risk of hepatic subcapsular hematoma rupture, DIC, and placental abruption.

Prevention, Antihypertensives & Seizure Prophylaxis

Prophylaxis: Low-dose aspirin (81 mg/day) initiated between 12 and 16 weeks gestation for patients at high risk for preeclampsia (prior preeclampsia, multifetal gestation, chronic hypertension, pregestational diabetes, renal disease, autoimmune disease).

Acute Antihypertensive Therapy: Indicated for severe hypertension ( BP ≥160/110 mmHg ) to reduce stroke risk. First-line agents include:

Intravenous Labetalol: Combined alpha-1 and beta-blocker. Avoid if maternal bradycardia (<60 bpm) or severe asthma.

Intravenous Hydralazine: Direct vasodilator. Can cause reflex tachycardia and headache.

Oral Immediate-Release Nifedipine: Calcium channel blocker. Preferred if IV access is delayed.

Note: ACE inhibitors, ARBs, and direct renin inhibitors are strictly teratogenic (cause renal dysgenesis, oligohydramnios, skull hypoplasia) and contra-indicated in all trimesters.

Seizure Prophylaxis: Intravenous Magnesium Sulfate (MgSO4) is the agent of choice for seizure prevention in preeclampsia with severe features and for seizure treatment in eclampsia. Administered as a 4–6 g IV loading dose over 15–20 minutes followed by 1–2 g/hour continuous IV maintenance infusion for 24 hours postpartum.

Magnesium Toxicity Monitoring: Loss of deep tendon reflexes (patellar reflex) occurs at therapeutic levels of 4–7 mEq/L (loss of DTRs at 8–12 mEq/L; respiratory depression at 12–15 mEq/L; cardiac arrest at >15 mEq/L). Monitor hourly urine output (>30 mL/hr), respiratory rate (>12/min), and patellar reflexes.

Antidote for Magnesium Toxicity: Intravenous Calcium Gluconate (1 g IV over 2–5 minutes) .

Timing of Delivery:

Preeclampsia without severe features: Delivery at 37 0/7 weeks gestation .

Preeclampsia with severe features / HELLP syndrome: Delivery at ≥34 0/7 weeks gestation (or immediately at any gestational age if maternal/fetal condition deteriorates, e.g., eclampsia, DIC, abruption, refractory severe BP).

Gestational Diabetes Mellitus (GDM)

Gestational diabetes arises from human placental lactogen (hPL / human chorionic somatomammotropin) inducing maternal insulin resistance in the 2nd and 3rd trimesters to ensure adequate glucose delivery to the fetus.

Screening & Diagnosis (2-Step Method at 24-28 weeks):

Step 1: 1-hour 50g Glucose Challenge Test (GCT). Serum glucose ≥130–140 mg/dL is positive.

Step 2: Diagnostic 3-hour 100g Oral Glucose Tolerance Test (OGTT) following an 8-12 hour fast. GDM is diagnosed if ≥2 values equal or exceed Carpenter-Coustan thresholds:

  • Fasting: ≥95 mg/dL
  • 1-Hour: ≥180 mg/dL
  • 2-Hour: ≥155 mg/dL
  • 3-Hour: ≥140 mg/dL

Management Protocols:

First-line: Nutritional modification (33-40% complex carbohydrates) and light exercise (30 mins post-meal walking).

Glycemic Targets: Fasting blood glucose <95 mg/dL , 1-hour postprandial <140 mg/dL , or 2-hour postprandial <120 mg/dL .

Pharmacotherapy: If glycemic targets are not achieved after 1–2 weeks of dietary modification, subcutaneous insulin is the first-line pharmacotherapy of choice (does not cross the placenta). Metformin and glyburide are second-line options.

Fetal & Neonatal Complications: Fetal hyperinsulinemia driven by maternal hyperglycemia leads to fetal macrosomia (EFW >4,500 g), shoulder dystocia, neonatal hypoglycemia (abrupt loss of maternal glucose supply post-delivery while fetal insulin remains high), polycythemia, hyperbilirubinemia, hypocalcemia, and delayed lung maturity (hyaline membrane disease).

Postpartum Management: Discontinue insulin immediately post-delivery. Perform a 2-hour 75g OGTT at 4–12 weeks postpartum to screen for persistent type 2 diabetes mellitus.

Early Pregnancy Loss & Ectopic Pregnancy

Ectopic Pregnancy: Implantation outside the endometrial cavity, most commonly in the ampulla of the fallopian tube (95%) . Classic presentation: amenorrhea, lower abdominal pain, and vaginal bleeding .

Evaluation: Transvaginal ultrasound (TVUS) and quantitative serum beta-hCG. The beta-hCG discriminatory zone (1,500–2,000 mIU/mL) is the level at which an intrauterine gestational sac should reliably be visible on TVUS. An empty uterus with beta-hCG above the discriminatory zone strongly suggests ectopic pregnancy.

Medical Management (Methotrexate): Folic acid antagonist that inhibits DNA synthesis in rapidly dividing trophoblastic tissue. Indications for methotrexate:

  • Hemodynamically stable patient with no severe abdominal pain
  • Unruptured ectopic mass <3.5 cm in diameter
  • No fetal cardiac activity on ultrasound
  • Baseline serum beta-hCG <5,000 mIU/mL
  • Normal baseline hepatic and renal function, and reliable patient follow-up

Surgical Management (Laparoscopic Salpingostomy / Salpingectomy): Indicated for hemodynamically unstable patients, signs of tubal rupture (peritonitis, hemoperitoneum), failed methotrexate therapy, or contraindications to methotrexate.

Spontaneous Abortion Subtypes: Defined as pregnancy loss prior to 20 weeks gestation.

Threatened Abortion: Vaginal bleeding, closed cervical os, fetal cardiac activity present on ultrasound.

Inevitable Abortion: Vaginal bleeding, cramping, open cervical os , products of conception visible at os or internal os dilated, no tissue passed yet.

Incomplete Abortion: Vaginal bleeding, severe cramping, open cervical os , partial passage of products of conception with retained tissue in uterus.

Complete Abortion: Vaginal bleeding/cramping resolved, closed cervical os , complete passage of all products of conception , empty uterine cavity on ultrasound.

Missed Abortion: Nonviable fetus retained in utero, closed cervical os , no vaginal bleeding or cramping.

Third-Trimester Hemorrhage & Placental Disorders

Third-trimester vaginal bleeding is an obstetric emergency requiring immediate maternal stabilization and fetal heart rate evaluation.

Feature Placenta Previa Placental Abruption (Abruptio Placentae) Vasa Previa

Etiology Placenta implants over internal cervical os Premature separation of placenta from decidua basalis Fetal vessels course unprotected through membranes over internal os

Clinical Presentation Painless , bright red vaginal bleeding Painful , dark vaginal bleeding with severe uterine tenderness Painless bleeding occurring immediately upon rupture of membranes

Uterine Tone Normal, soft, non-tender uterus Hypertonic, rigid, "woody", tender uterus Normal uterine tone

Fetal Status Reassuring unless maternal shock occurs Non-reassuring (late decelerations, bradycardia) Rapid fetal bradycardia / sinusoidal tracing (fetal exsanguination)

Risk Factors Prior C-section, multiparity, prior uterine surgery Maternal hypertension, cocaine use, trauma, smoking Succenturiate placenta, velamentous cord insertion, IVF

Contraindication Digital vaginal exam strictly contraindicated Rapid vaginal exam delayed until previa excluded Digital exam contraindicated

Management Scheduled C-section at 36 0/7–37 6/7 weeks Emergency C-section if fetal/maternal distress Emergency C-section immediately upon membrane rupture [ Suspected Preeclampsia (BP ≥140/90 mmHg after 20 weeks) ]

  • |
  • +---------------------------+---------------------------+
  • | |
  • [ Check Proteinuria & Severe Criteria ] [ Chronic Hypertension ]
  • Urine Protein ≥300 mg/24h or PCR ≥0.3 (BP ≥140/90 pre-pregnancy
  • Severe BP ≥160/110 mmHg or <20 weeks gestation)
  • Platelets <100,000/mcL
  • SCr >1.1 mg/dL or ALT/AST ≥2x normal
  • Pulmonary Edema or Cerebral/Visual Symptoms
  • |
  • +-------+-------+
  • | |
  • [ Present ] [ Absent ] ---> [ Gestational Hypertension ]
  • | (BP ≥140/90, no proteinuria/severe features)
  • v
  • [ Preeclampsia Confirmed ]
  • |
  • +-------------------------------+-------------------------------+
  • | |
  • [ Any Severe Feature Present? ] [ No Severe Features ]
  • (BP ≥160/110, Platelets <100k, |
  • AST/ALT 2x, SCr >1.1, Headache/Scotomas) v
  • | [ Delivery at 37 0/7 Weeks ]
  • +-------------------------------+
  • | Yes | Eclampsia (Seizures) / HELLP
  • v v
  • [ Preeclampsia with Severe Features ] [ Emergency Stabilization ]
  • |
  • |- 1. Antihypertensives for BP ≥160/110 (IV Labetalol, IV Hydralazine, Oral Nifedipine)
  • |- 2. IV Magnesium Sulfate Loading (4–6 g IV) + Maintenance (1–2 g/hr) for Seizure Prophylaxis
  • |- 3. Delivery at ≥34 0/7 Weeks (or immediate delivery if maternal/fetal decompensation)